Tools

ETNB

89bio Inc · NASDAQ

Performance

+38.73%

1W

+23.23%

1M

+20.15%

3M

+5.61%

6M

+22.76%

YTD

-3.03%

1Y

Profile

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Technical Analysis of ETNB 2025-01-31

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90 and a Technical Score of 85, indicating robust upward momentum. However, the Oscillators Score of 46 suggests a neutral stance, implying potential caution despite the overall positive outlook.
Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

See more ...

Stock Analysis of ETNB

Created with Highcharts 11.1.0212111118080770100
QualityGrowthMomentumValue4

Stock Rank

See more ...

Recent News & Updates

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.